Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 9/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 9/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CPN1 | P15169 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1666938 | 0.88 | AKR1C3 (0.47) | NOS1AKR1C3AKR1C2AKR1C1PTGS1 | |
| SCHEMBL4390456 | 0.86 | AKR1C3 (0.46) | AKR1C3AKR1C2AKR1C1PTGS1POLB | |
| SCHEMBL289355 | 0.84 | PPARA (0.50) | AKR1C3AKR1C2AKR1C1KDM4A | |
| SCHEMBL2891180 | 0.81 | AKR1C3 (0.47) | AKR1C3AKR1C2AKR1C1PTGS1POLB | |
| Benzylamine SCHEMBL726584 | 0.81 | POLB (0.53) | POLBKDM4A | |
| SCHEMBL31477054 | 0.80 | AKR1C3 (0.46) | AKR1C3AKR1C2AKR1C1PTGS1POLB | |
| SCHEMBL21609292 | 0.80 | PTGS1 (0.49) | NOS1AKR1C3AKR1C2AKR1C1PTGS1 | |
| Hydrochloric Acid SCHEMBL11362424 | 0.80 | TAAR1 (0.46) | NOS1TAAR1AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL4392393 | 0.78 | AKR1C3 (0.42) | AKR1C3AKR1C2AKR1C1PTGS1POLB | |
| SCHEMBL750097 | 0.78 | CPN1 (0.71) | AKR1C3AKR1C2AKR1C1PTGS1CPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629358-B2 | Compounds useful for the treatment of diseases | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-20050234097-A1 | Compounds useful for the treatment of diseases | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| EP-1577291-A1 | Phenylethanolamine derivatives as beta-2 agonists | Pfizer Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234097-A1 | Compounds useful for the treatment of diseases | LTC4S, CYP11B2, CYP11B1 | NOS1 641/4885TAAR1 1799/4885DRD2 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.